Zihai Li
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
Disease recurrence is the main cause of treatment failure after CD19-directed CAR T cells and is often due to CD19 antigen loss, stability and/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain. Preclinical studies demonstrated potent, antigen-specific cytotoxicity in both in vitro and in vivo lymphoma models. We then conducted a first-in-human phase I trial in patients with relapsed/refractory B-cell malignancies. Fifteen patients received fresh infusions at a median vein to vein time of 7 days, at doses of 0.5-2×10⁶ cells/kg. No severe cytokine release syndrome nor immune effector cell-associated neurotoxicity syndrome occurred. Overall response rate was 50%, including complete responses in 83% of lymphoma patients. One-year overall survival rate was 61%, with durable remissions observed in lymphoma. CAR T expansion did not correlate with dose or response. T-cell exhaustion in apheresis cells correlated with progressive disease. Trispecific CAR T cells are safe and potentially active in non-Hodgkin lymphoma.
Year:
2026
The exhaustion of tumor-infiltrating CD8 + T cells poses a substantial challenge in cancer immunotherapy, with mitochondrial health essential for sustaining T cell functionality. Mitophagy, a critical process for mitochondrial quality control, is severely impaired in exhausted CD8 + T cells, yet the underlying mechanisms remain unclear. We identified ubiquitin-specific protease 30 (USP30), a mitochondrial deubiquitinase that inhibits mitophagy, as a key factor up-regulated in exhausted CD8 + T cells. Notably, prolonged antigen stimulation triggers the T cell receptor and nuclear factor of activated T cell 1 signaling, which drives the transcriptional up-regulation of USP30. Excitingly, our interventions targeting USP30 through genetic deletion or pharmacological inhibition effectively restored mitophagy, improved mitochondrial fitness, and rejuvenated CD8 + T cell effector functions. These interventions reinvigorated antitumor responses and markedly suppressed tumor growth. Our findings establish USP30 as a critical regulator of mitophagy and a promising therapeutic target for reversing T cell exhaustion and enhancing the efficacy of cancer immunotherapy.
Year:
2025
Background Bladder cancer is unique among visceral malignancies in that urine, which can be easily obtained, has prolonged contact with bladder tumors. Urinary biomarkers offer the potential to provide insight into the host and tumor immune microenvironment to guide therapeutic strategies. We evaluated the immune cellular composition of urine (urine-derived lymphocytes (UDLs)) versus tumor (tumor-infiltrating lymphocytes (TILs)). Methods We employed high-dimensional flow cytometry analyses on immune cells from tumors (TILs), urine (UDLs), and peripheral blood (peripheral blood mononuclear cells) among patients with bladder cancer. We performed multiplexed immunofluorescence (mIF) of matched tumors to provide spatial context to our findings, comparing deep/invasive and superficial/urine-facing regions of matched tumors. Results Our findings suggest that the CD4 + and CD8 + T cell subsets of UDLs characterized by flow cytometry had similar phenotypic profiles to those found in TILs (cell clusters quantified by multidimensional scaling and differentiation states). Results of mIF imaging with a panel of phenotypic and functional T cell markers suggested that UDLs reflected TILs in both superficial and deep tumor sections. We also found sex-dependent patterns in TILs and UDLs, indicating the male bladder cancer tumor microenvironment is enriched in exhausted CD4 + and CD8 + T cells, while the female bladder cancer microenvironment is enriched for activated T cells. Conclusions Assessment of UDLs opens avenues of non-invasive biomarker development in clinical settings where bladder cancer TILs are hypothesized to predict clinical response. UDLs may also reflect sex-based differences in antitumor immunity.
Year:
2025
Supplementary Figure S1 shows PD-1 blockade therapy combined with NK cell depletion improves tumor control and increases CD8⁺ T cell infiltration. Supplementary Figure S2 shows the combination of NK cell depletion and ICB is most effective when NK cells are depleted at an early stage. Supplementary Figure S3 shows NKRT accumulation is tumor-site specific. Supplementary Figure S4 shows phenotypic changes in CD4⁺ T cells upon NK cell depletion. Supplementary Figure S5 shows NKRTs are antigen-specific and exhibit enhanced tumor-controlling efficacy when combined with ICB. Supplementary Figure S6 shows NKRT formation depends on the timing of NK cell depletion. Supplementary Figure S7 shows NK cell depletion delays CD8⁺ T cell exhaustion in day 15 MC38 tumors. Supplementary Figure S8 shows NK cell depletion delays CD8⁺ T cell exhaustion in day 20 MC38 tumors. Supplementary Figure S9 shows NK cell depletion improves tumor control in the ACT setting. Supplementary Figure S10 shows distinct gene expression profiles in CD8⁺ T cells following NK cell depletion. Supplementary Figure S11 shows volcano plots of differentially expressed genes under specific conditions. Supplementary Figure S12 shows elevated p-STAT3 and p-STAT5 levels in CD8⁺ T cells from NK cell-depleted tumors. Supplementary Figure S13 shows cytokines play a critical role in NKRT formation and anti-tumor activity. Supplementary Figure S14 shows computational model fits of tumor growth curves and CD8⁺ T cell dynamics. Supplementary Figure S15 shows phenotypic variation in tumor-infiltrating NK cells across tumor models. Supplementary Figure S16 shows expression patterns of tissue-resident markers in CD8⁺ T cells and NK cell proportions in responders versus non-responders to immunotherapy.
Year:
2025
Spatial mapping of NK cells. A, Percentage of CD8 + T-cell subsets and NK cells of all immune cells plotted among three tumor-infiltrating lymphocytes: “absent” (cold), “non-brisk” (excluded), and “brisk” (hot) assessed by pathologist grouping all samples and splitting by response for the NK cells. Data analyzed by a two-sided Wilcoxon test and bold = P B, Representative multiplex immunofluorescence staining on lesions from an NR for whom NK cells were detected in the immune-infiltrating patch. Green = GNLY, red = melanoma, orange = CD3, and blue = CD8. Arrows point NK cells, and the dashed line represents tumor border. C, Density per square millimeter of NK cells compared between three different tumoral regions, response, and time point. Data analyzed by a two-sided Wilcoxon test and bold = P D, Spatial plots of all identified cells from two examples of immune-excluded tumors from skin metastasis biopsies. Arrows point toward NK cells, and the dashed line represents tumor border. E, Dotplot of expression of NK-related genes by NK cells plotted among immunophenotype and time point; BT cold, n = 1; BT excluded, n = 1; OT cold, n = 1; and OT excluded, n = 5; ( F ) Heatmaps of neighborhood enrichment of cell types/states identified using Xenium spatial transcriptomics for one BT excluded sample and five OT excluded samples. Cells for which abundance was z -scores from a permutation test, indicating how frequently each pair of cell types was observed as neighbors compared with a randomly permuted spatial distribution. G, Stacked bar representing percentages of 20 immune cells surrounding NK cells, plotted between one BT excluded sample and five OT excluded samples. CAF, cancer-associated fibroblast; cDC1, conventional type 1 DCs; cDC2, conventional type 2 DCs; R, responder; Treg, regulatory T cell.
Year:
2025
Dissecting the immune compartment of the melanoma ecosystem under immunotherapy pressure. A, Schematic describing the design of the SPECIAL clinical study, the timing of sample collection, number of patients enrolled, and samples collected, and single-cell (spatial) methodologies deployed for their in-depth characterization. B, UMAP of the CD8 + T cells and NK cells identified by unsupervised Louvain clustering of the subset of CD8 + T/NK cells including samples from both time points. C, Dotplot of the top representative discriminatory marker genes of the cells presented in B including samples from both time points. Size of the dot represents the number of cells expressing the gene and color reflects the expression level. D, UMAP of all immune cell types and states identified by summarizing unsupervised Louvain clustering and subclustering of myeloid and CD8 + T/NK cells including samples from both time points. E, Percentage of CD8 + T-cell subsets and NK cells of all immune cells compared among Before treatment (BT) and On treatment (OT) samples and both response groups (two-sided Wilcoxon test, bold text points to significant differences = P F, Dotplot showing expression of NK-related genes, oxidative phosphorylation (OXPHOS), and chemokines/cytokine genes (highly discriminating group 1, 2, and 3 of NK cells) acquired from Netskar and colleagues ( 29 ) and NK functional genes acquired from Tang and colleagues ( 8 ) and other genes within NK cell population across response and time point groups. Size of the dot represents the number of cells expressing the gene and color reflects the expression level. G, Violin plot showing log 2 -transformed gene score (AUCell) ratios (chemokine/cytokine signature vs. NK cytotoxicity signature), calculated based on genes shown in E . cDC1, conventional type 1 DCs; cDC2, conventional type 2 DCs; R, responder; NR, Non-responder; UMAP, Uniform Manifold Approximation and Projection. ( A, Created with BioRender.com .)
Year:
2025
Immune checkpoint blockers (ICB) targeting the PD-1/PD-L1 axis represent established therapies for many cancers. However, resistance occurs in most patients due to complex immune-suppressive mechanisms in the tumor microenvironment. NK cells can play effector roles in tumor control, but their impact on T-cell dysfunction and ICB efficacy remains controversial. Through genetic and antibody-mediated NK cell depletion, we found that a subset of tumor-associated NK cells plays a negative role in ICB sensitivity; they further impede CD8 + T-cell differentiation toward a CD69 + BCL2 + EOMES + GZMB + TIM3 − GITR − phenotype. Mechanistically, the retinoic acid receptor α–dependent differentiation program in CD8 + T cells is hindered by tumor-infiltrating NK cells via competition for IFNα and IL-2. Finally, we observed that lower frequencies of NK cells correlate with better clinical responses to ICBs in patients with cancer. These findings suggest potential avenues for enhancing CD8 + T cell–centered immunotherapy by targeting regulatory NK cells. Significance: Although NK cells are traditionally viewed as antitumor effectors, our study uncovers their unexpected suppressive role in CD8 + T cell–based immunotherapy. By competing for cytokines, they disrupt retinoic acid receptor α–driven CD8 + T-cell differentiation and limit ICB efficacy. Clinically, reduced NK cell presence is associated with an enhanced immunotherapy response. See related commentary by Galvez-Cancino et al., p. 1777 See related article by Pozniak et al., p. 1819
Year:
2025
NK cells as modulators of ICB sensitivity in mice. A, Immunofluorescence of YUMM5.2 and ( B ) NRAS;Ink4a tumors. Tumors were stained for a melanoma marker (PDGFRa for YUMM5.2 and SOX10 for NRAS;Ink4a ) and for CD45 and CD3ε to map the T-cell infiltration. Counterstaining was performed with DAPI. C, Schematic representation of NK and T-cell infiltration in the NRAS;Ink4a and YUMM5.2 tumors. D, Schematic representation of the therapeutic regimen used with YUMM5.2 and NRAS;Ink4a tumors. E, Growth curves of YUMM5.2 (top left) and NRAS;Ink4a tumors (bottom left) in vivo ( n ≥ 5 per cohort (control, αPD-1, aNK1.1, and αPD-1 + aNK1.1). A Welch-corrected t test was performed on the doubling time of tumors upon exponential fitting (*, P P NRAS;Ink4a tumors (bottom right) in vivo ( n ≥ 5 per cohort. A log-rank Mantel–Cox test was used; *, P P P F, Cryosection immunofluorescence showing the overall immune infiltrate of NRAS;Ink4a tumors across cohorts. Tumor cells were identified by S100 and immune cells by CD45. Counterstaining was performed with DAPI. The dashed line marks the separation between tumor and immune areas. Quantification of overall immune infiltration in NRAS;Ink4a tumors (number of CD45 + of all DAPI-positive cells, with n ≥ 6 per cohort and data analyzed with a Welch-corrected t test; *, P P G, Stacked bar plot showing proportions of immune cell types from the NRAS;Ink4a and YUMM5.2 tumors across conditions based on the scRNA-seq experiment. For each condition, at least four mice were pooled (see “Methods”). H, Growth curves (left) and doubling time calculation (right) of NRAS;Ink4a tumors in vivo treated with αPD-1 and/or aNK1.1 in the presence/absence of CD8 + T-cell depletion ( n = 4 per cohort and a Welch-corrected t test was performed on the doubling time of tumors upon exponential fitting; **, P C and D, Created with BioRender.com .)
Year:
2025
Supplementary Table 1 shows the list of antibodies used in this study. Supplementary Table 2 shows the input data and variables used for computational modeling. Supplementary Table 3 shows parameter estimates and confidence intervals for modeled cell populations. Supplementary Table 4 shows patient demographics, tumor characteristics, and treatment regimens.
Year:
2025
Pharmacologic targeting of NK cells. A, Uniform Manifold Approximation and Projection (UMAP) of re-clustered NK cells from the NRAS;Ink4a and YUMM5.2 tumors (left), selected genes expression between NK cell clusters (middle), and proportions of NK cells from the NRAS;Ink4a and YUMM5.2 tumors compared between control- and αPD-1–treated condition (right) based on the scRNA-seq experiment. B, Dot plot of the expression of selected genes between NRAS;Ink4a and YUMM5.2 tumors in NK cells only based on the scRNA-seq experiment. C, Volcano plot representing differentially expressed proteins in NK cells from the NRAS;Ink4a tumor between control and αPD-1 treatment. Significantly expressed proteins were considered based on the adjusted P value > 10e–3 based on the CITE-seq experiment. D, Growth curves (left) and doubling time calculation (right) of NRAS;Ink4a tumors in vivo treated with αPD-1, JMS-17-2, and CD38 ( n ≥ 4 per cohort and a Welch-corrected t test was performed on the doubling time of tumors upon exponential fitting; **, P E, Quantification of immune cells (CD45 + ), NK cells (CD45 + NKP46 + ), CD8 + T cells (CD45 + CD3 ε + CD8 α + ), and macrophages (CD45 + F4/80 + ) in multiplexed immunofluorescence images (each dot corresponds to a single tumor; data analyzed with a Welch-corrected t test; *, P P 2 in proximity to the tumor border.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (26)
David Carbone
Ohio State University Medical Center
Yvan Saeys
department of social work and social pedagogy ghent university ghent belgium
Christin E. Burd
Professor
Ohio State University
Sizun Jiang
Assistant Professor
Harvard Medical School
Garry Nolan
Professor and Carlota A. Harris Professor
Stanford University School of Medicine
Nicholas Denko
Professor
Ohio State University
Marcos de Lima
Ohio State University
Kai He
The Ohio State University Wexner Medical Center
Brian Searle
Career Scientist
Mayo Clinic
Patrick Matthys
PI, Professor
KU Leuven
Tong Xiao
Ohio State University
Diether Lambrechts
Science Director
KU Leuven
SAMHITA CHAUDHURI
Ohio State University
Jennifer A. Woyach
-
Dongjun Chung
Professor
Ohio State University
Narendranath Epperla
The Ohio State University Comprehensive Cancer Center
Haitao Wen
Assistant Professor
Ohio State University
Bethany Mundy-Bosse
Associate Professor
Ohio State University
Anjun Ma
Assistant Professor
Ohio State University
Jean-Christophe Marine
Professor
KU Leuven
Qin Ma
Vice Chair for Research
Ohio State University
Dong Xu
Professor
University of South Florida
Dan Barouch
Beth Israel Deaconess Medical Center
Oliver Bechter
University Hospitals Leuven
William E. Carson, III
Professor
Ohio State University
Francesca Maria Bosisio
University Hospitals Leuven
Make your next move.
Prepare your application
Review drafts before you send them.